XNAS · Healthcare · Biotechnology
Milestone Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of cardiovascular medicines. Its approved product CARDAMYST (etripamil) nasal spray is available in the United States and is the self-administered treatment for use by patients anywhere, anytime an attack of PSVT occurs. It operates in single segment.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-13 | Q1 2026 | 0.14 | -0.20 | -242.86% | $238,000 | ❌ Miss | +1.58% | -12.79% | — |
| 2026-03-20 | Q4 2025 | -0.18 | -0.16 | +11.11% | $1.5M | ✅ Beat | +2.94% | -23.53% | +50.00% |
| 2025-11-12 |
| Q3 2025 |
| -0.17 |
| -0.12 |
| +29.41% |
| $0 |
| ✅ Beat |
| — |
| — |
| — |
| 2025-08-12 | Q2 2025 | -0.18 | -0.20 | -11.11% | $0 | ❌ Miss | +0.00% | +0.60% | +15.06% |
| 2025-03-13 | Q4 2024 | -0.15 | -0.19 | -26.67% | $0 | ❌ Miss | +6.90% | -3.94% | -59.03% |
| 2024-05-13 | Q1 2024 | -0.26 | -0.21 | +19.23% | $0 | ✅ Beat | +1.18% | +2.65% | -16.47% |
| 2024-03-21 | Q4 2023 | -0.31 | -0.32 | -3.23% | $0 | ❌ Miss | — | — | — |
| 2023-11-13 | Q3 2023 | -0.38 | -0.35 | +7.89% | $0 | ✅ Beat | -4.27% | -2.56% | +7.26% |
Showing last 8 quarters.